Latest news with #GeronCorp
Washington Post
07-05-2025
- Business
- Washington Post
Geron: Q1 Earnings Snapshot
FOSTER CITY, Calif. — FOSTER CITY, Calif. — Geron Corp. (GERN) on Wednesday reported a loss of $19.8 million in its first quarter. On a per-share basis, the Foster City, California-based company said it had a loss of 3 cents.
Yahoo
18-04-2025
- Business
- Yahoo
Is Geron Corp. (NASDAQ:GERN) the Most Promising Penny Stock According to Analysts?
We recently published a list of the . In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against other promising penny stocks. Solus' Dan Greenhaus, and Invesco's Brian Levitt together appeared on CNBC's 'Closing Bell' on April 15 to talk about tariffs, market uncertainty, and risk concerns. The discussion started with Dan Greenhaus expressing his belief that many worst-case scenarios are already priced into the market. He acknowledged that he's cautious but not overly worried. He pointed out recent events, like the exemptions on auto part imports and the 90-day delay on tariff implementation, as evidence that President Trump is listening to advisors and avoiding pushing toward extreme outcomes. Greenhaus attributed these actions to the rebound seen in the stock market. At the same time, he agreed that the administration has been rather inconsistent, in the context of Morgan Stanley's comment that investors should prepare for more inconsistencies. But he argued that many investors are assuming scenarios closer to the worst rather than the best. He emphasized that while frightening predictions about skyrocketing prices are taking over media right now, these scenarios are unlikely to materialize. Brian Levitt built on Greenhaus' optimism while acknowledging the ongoing uncertainty as well. He attributed this uncertainty to the reliance on decisions from the White House rather than traditional policy mechanisms. He compared the current situation to 2018 when markets fell 20% in a quarter before rebounding due to trade pauses and Fed intervention. He cautioned that the current S&P 500 multiples are not at recession levels so there are potential downside risks if uncertainty remains. While Levitt thinks that business investment and consumer confidence metrics show signs of prolonged volatility, Greenhaus further emphasizes that periods of heightened uncertainty often end up presenting long-term investment opportunities. He acknowledged risks such as sudden tariff increases but also encouraged investors to take advantage of these moments when risk premiums rise. We sifted through the Finviz stock screener to compile a list of the top penny stocks that were trading below $5 and had the highest analysts' upside potential (at least 40%). The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q4 2024, which was sourced from Insider Monkey's database. Note: All data was sourced on April 15. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug. Share Price as of April 15: $1.32 Number of Hedge Fund Holders: 46 Average Upside Potential as of April 15: 240.91% Geron Corp. (NASDAQ:GERN) is a commercial-stage biopharmaceutical company that develops therapeutics for oncology. It offers RYTELO, which is a telomerase inhibitor for the treatment of adult patients with low to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS) with transfusion-dependent anemia. RYTELO was approved in the US in June 2024. Later in August 2024, RYTELO also gained favorable placement in the NCCN guidelines and received a Category 1 treatment recommendation for second-line RS-positive and RS-negative patients. Since its launch in the US, RYTELO made $76.5 million in net product revenue by year-end. In Q4 2024 alone, RYTELO made $47.5 million in net product revenue. RYTELO has received a positive opinion in Europe, with a final EU approval decision expected in H1 2025. This will potentially lead to a 2026 EU launch. On March 12, Wedbush analyst Robert Driscoll maintained a Buy rating on the stock with a $7 price target. Payers that cover about 80% of US-insured lives have favorable coverage for RYTELO. The US market for eligible lower-risk MDS patients is estimated to be ~15,400 in 2025. ClearBridge Small Cap Growth Strategy stated the following regarding Geron Corporation (NASDAQ:GERN) in its Q1 2025 investor letter: 'We continued to generate a number of compelling new ideas, adding five new investments that we still held at quarter end: Glaukos, Rocket Lab USA, Karman Holdings (through its IPO), Archrock, Hims & Hers and Geron Corporation (NASDAQ:GERN). Overall, GERN ranks 5th on our list of the most promising penny stocks according to analysts. While we acknowledge the growth potential of GERN, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than GERN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
16-04-2025
- Business
- Yahoo
Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the . In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against other biotech penny stocks. Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas. First the vaccine approvals and the subsequent resurgence of new vaccines over the past two decades, and then the establishment of the cell and gene therapy field that he's credited for. He was involved in developing policies aimed at optimizing the process of bringing several innovative products to the market. Following his resignation, a substantial number of other departures are also anticipated, which implies upcoming destabilization at the FDA for its existing expertise and processes. Stifel head of biotech research Paul Matteis suggests looking for biotech names not dependent on the FDA while this sector uncertainty lasts. On March 31, Paul Matteis appeared on CNBC's 'The Exchange' and noted that biotech investors, particularly those who are focused on developmental-stage companies, are now facing risk. These include scientific, clinical trials, commercial, patent, competition, and regulatory risks. Hence, investors now need to be more selective about their stock selections. Previously, the FDA has been a stabilizing force for the biotech sector and is known for accelerating approvals in areas such as rare diseases and biomarkers. But recent developments have introduced unpredictability. Matteis highlighted that there could be short-term delays in drug approvals due to personnel changes at the FDA, such as the recent departure of the head of the Center for Drug Evaluation and Research (CEDAR). Investors may even need to reevaluate agreements between companies and the FDA regarding drug approvals. While this doesn't make biotech investments completely unsustainable, it does shift the focus toward companies with more predictable growth prospects. This could point to specifically commercial-stage firms or those less reliant on FDA consistency. Talking about vaccine stocks particularly, Matteis pointed out that as much as Peter Marks influenced vaccine-related decisions, he also impacted broader areas like gene therapies and oncology. He fostered innovation through programs like breakthrough therapy designations and initiatives that were aimed at streamlining approvals. Investors are now gravitating toward companies with de-risked profiles that are less dependent on FDA flexibility. Matteis noted that the companies relatively outperforming right now are those that have their success tied to commercial launches rather than regulatory decisions. We sifted through ETFs, stock screeners, and financial media reports to compile a list of the top biotech penny stocks that were trading below $5 as of April 14. We then selected the 13 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey's database which tracks the moves of over 1000 elite money managers. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A close-up of a laboratory technician in a laboratory, measuring a newly developed biopharmaceutical drug. Share Price as of April 14: $1.38 Number of Hedge Fund Holders: 46 Geron Corp. (NASDAQ:GERN) is a commercial-stage biopharmaceutical company that develops therapeutics products for oncology. It offers RYTELO (imetelstat) which is a telomerase inhibitor for the treatment of adult patients with low to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. RYTELO was approved in the US in June 2024 for specific lower-risk MDS patients. In Q4 2024, which was RYTELO's second full quarter on the market, the candidate generated $47.5 million in net product revenue. Since launch through year-end 2024, revenue reached $76.5 million. Payers covering about 80% of US-insured lives have favorable coverage for RYTELO. The estimated US market for eligible lower-risk MDS patients in 2025 is ~15,400. RYTELO has received a positive opinion in Europe for certain MDS patients, with a final EU approval decision expected in H1 2025, potentially leading to a 2026 EU launch. Geron Corp. (NASDAQ:GERN)ended 2024 with ~$503 million in cash and expects to reach profitability without further funding based on RYTELO's sales growth. ClearBridge Small Cap Growth Strategy stated the following regarding Geron Corporation (NASDAQ:GERN) in its Q1 2025 investor letter: 'We continued to generate a number of compelling new ideas, adding five new investments that we still held at quarter end: Glaukos, Rocket Lab USA, Karman Holdings (through its IPO), Archrock, Hims & Hers and Geron Corporation (NASDAQ:GERN). Overall, GERN ranks 1st on our list of the best biotech penny stocks to buy according to hedge funds. While we acknowledge the growth potential of GERN, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than GERN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
